Institutional shares held 47,561
0 calls
0 puts
Total value of holdings $121K
$0 calls
$0 puts
Market Cap $7.94M
3,100,940 Shares Out.
Institutional ownership 1.53%
# of Institutions 2


Latest Institutional Activity in SNOA

Top Purchases

Q2 2024
Citadel Advisors LLC Shares Held: 195K ($500K)
Q2 2024
Geode Capital Management, LLC Shares Held: 86.6K ($222K)
Q2 2024
Jane Street Group, LLC Shares Held: 45.3K ($116K)
Q2 2024
Hrt Financial LP Shares Held: 21.5K ($55.1K)
Q2 2024
Ubs Group Ag Shares Held: 11.9K ($30.5K)

Top Sells

Q2 2024
Tower Research Capital LLC (Trc) Shares Held: 8.27K ($21.2K)
Q2 2024
Wells Fargo & Company Shares Held: 33 ($84.5)
Q1 2024
Millennium Management LLC Shares Held: 13K ($33.3K)
Q4 2023
Black Rock Inc. Shares Held: 2.27K ($5.8K)
Q3 2023
Renaissance Technologies LLC Shares Held: 14K ($35.9K)

About SNOA

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.


Insider Transactions at SNOA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
176K Shares
From 4 Insiders
Grant, award, or other acquisition 176K shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on SNOA

Follow Sonoma Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SNOA shares.

Notify only if

Insider Trading

Get notified when an Sonoma Pharmaceuticals, Inc. insider buys or sells SNOA shares.

Notify only if

News

Receive news related to Sonoma Pharmaceuticals, Inc.

Track Activities on SNOA